Why "dose equivalence" between different incretin analogues is a weak concept
There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which is a different claim from "slower is fine".
The conclusion is tentative; the arithmetic underneath it is not.
The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.
Post #61 put the caveat in the right place and I want to underline it.
The most common practical error is not the schedule at all — it is losing track of which step you are on after a break, and then resuming at the top rather than re-approaching it.
That is the version I use. It may not be the version that is correct.
Holding a dose indefinitely: the trials did not study indefinite holding at a non-maximum dose. The trials escalated to a target and then held that. What happens if you stay at an intermediate dose for years is not formally studied and extrapolation is the best available reasoning.
Small point, but it is the one that usually catches people.
Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.
The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat it as one.
Post #102 and I disagree about the size of the effect, not about the direction.
The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.
Second-hand, so weight it accordingly.
Read the full topic (134 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
What steady state means for the decision to escalate
What steady state means for the decision to escalate — that is the question, and I have not found it answered plainly anywhere I have looked. A question about steady state that I think has a definite answer,…
|
+31 | 35 | 2k | 1d |
|
About the Dosing & titration category
Schedules, escalation intervals, dose reductions, and the arithmetic that connects a vial to a syringe mark. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 350 | 4mo | |
|
Titrating on tolerability rather than on the calendar
On the subject in the title: Titrating on tolerability rather than on the calendar Working notes rather than a conclusion. An honest uncertainty about titrating on tolerability rather than a disguised…
|
2 | 31k | 13mo | |
|
The lowest dose that does anything: is that a real question?
Asking directly, because I could not find a straight answer: The lowest dose that does anything: is that a real question? I have read the maintained page on this and I still have a gap, so I am asking rather…
|
+100 | 111 | 9.1k | 5mo |
|
Micro-titration: a disputed topic, argued properly
Micro-titration: a disputed topic, argued properly Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers on…
|
+99 | 110 | 61k | 2d |
Related topics — sharing the tags tirzepatide, dose reduction, titration
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Escalating every six weeks instead of four: what I observed over eight months
Escalating every six weeks instead of four: what I observed over eight months — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
|
4 | 164 | 20mo | |
|
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported?
Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Something about Tirzepatide…
|
+109 | 122 | 3.6k | 2mo |
|
About the Semaglutide category
GLP-1 receptor agonist. Dosing, published trial data, tolerability, and formulation questions. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with…
|
4 | 4.2k | 11mo | |
|
How much of the diluent volume the powder itself displaces
Asking directly, because I could not find a straight answer: How much of the diluent volume the powder itself displaces Writing this out with the numbers in it, because "roughly" is how these go wrong. Vial:…
|
2 | 1.8k | 1d | |
|
About the Pharmacokinetics category
Half-life, accumulation, steady state, albumin binding, and why weekly dosing works. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
4 | 32k | 8mo |